Drug-induced vitiligo: a case/non-case study in Vigibase
Vitiligo
antibodies monoclonal
interferons
pharmacovigilance
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
11
10
2019
revised:
26
03
2020
accepted:
29
03
2020
pubmed:
5
4
2020
medline:
27
7
2021
entrez:
5
4
2020
Statut:
ppublish
Résumé
Vitiligo is a common depigmenting disorder ensuing the loss of epidermal melanocytes. It is a multifactorial disease with immunological, genetic and environmental factors including drug exposure. The purpose of the study was to investigate the drugs and therapeutic subclasses associated with vitiligo occurrence reported in VigiBase
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
736-742Informations de copyright
© 2020 Société Française de Pharmacologie et de Thérapeutique.
Références
Taïeb A., Picardo M. Clinical practice. Vitiligo. N. Engl. J. Med. (2009) 360 160-169.
Ezzedine K., Eleftheriadou V., Whitton M., van Geel N. Vitiligo. Lancet Lond. Engl. (2015) 386 74-84.
Gey A., Diallo A., Seneschal J. et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. Br. J. Dermatol. (2013) 168 756-761.
Richmond J.M., Frisoli M.L., Harris J.E. Innate immune mechanisms in vitiligo: danger from within. Curr. Opin. Immunol. (2013) 25 676-682.
van den Boorn J.G., Konijnenberg D., Dellemijn T.A.M. et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J. Invest. Dermatol. (2009) 129 2220-2232.
Guerra L., Dellambra E., Brescia S., Raskovic D. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr. Drug Metab. (2010) 11 451-467.
Bulbul A. Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer. Oxf. Med. Case Reports (2019) 2019 6.
Liu R.C., Consuegra G., Chou S., Fernandez Peñas P. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers. Clin. Exp. Dermatol. (2019) 44 643-646.
Kadono T. Immune-related adverse events by immune checkpoint inhibitors. Nihon Rinsho Meneki Gakkai Kaishi. (2017) 4 83-89.
Tregunno P.M., Fink D.B., Fernandez-Fernandez C., Lázaro-Bengoa E., Norén G.N. Performance of probabilistic method to detect duplicate individual case safety reports. Drug Saf. (2014) 37 249-258.
Lindquist M. VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf. J. (2008) 42 409-419.
WHO Collaboration Centre for Drug Statistics Methodology and Norwegian Institute of Public Health. Guidelines for ATC classification and DDD assignment. 2019. https://www.whocc.no/filearchive/publications/2019_guidelines_web.pdf. Accessed July 24, 2019.
Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet Lond. Engl. (2000) 356 1255-1259.
Bate A., Evans S.J.W. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol. Drug Saf. (2009) 18 427-436.
Linselle M., Sommet A., Bondon-Guitton E. et al. Can drugs induce or aggravate sleep apneas? A case-noncase study in VigiBase®, the WHO pharmacovigilance database. Fundam. Clin. Pharmacol. (2017) 31 359-366.
Babai S., Voisin A.L., Bertin C. et al. Occurrences and outcomes of immune checkpoint inhibitors-induced vitiligo in cancer patients: a retrospective cohort study. Drug Saf. (2020) 43 111-117.
Ramondetta A., Ribero S., Conti L. et al. Clinical and pathological relevance of drug-induced vitiligo in patients treated for metastatic melanoma with anti-PD1 or BRAF/MEK inhibitors. Acta Derm. Venereol. (2020) 100 adv00001.
Tkachenko E., Lin J.Y., Hartman R.I. Regional vitiligo induced by imiquimod treatment for in-transit melanoma metastases. JAAD Case Rep. (2019) 5 427-429.
Kim N.H., Lee J.B., Yun S.J. Development of vitiligo-like depigmentation after treatment of lentigo maligna melanoma with 5% imiquimod cream. Ann. Dermatol. (2018) 30 454-457.
Mashiah J., Brenner S. Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin. Exp. Dermatol. (2008) 33 74-76.
Jung J.M., Lee Y.J., Won C.H. et al. Development of vitiligo during treatment with adalimumab: a plausible or paradoxical response? Ann. Dermatol. (2015) 27 620-621.
Maruthappu T., Leandro M., Morris S.D. Deterioration of vitiligo and new onset of halo naevi observed in two patients receiving adalimumab. Dermatol. Ther. (2013) 26 370-372.
Toussirot E., Salard D., Algros M.-P., Aubin F. Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab. Ann. Dermatol. Venereol. (2013) 140 801-802.
Lu X., Gao Y., Ding Y. Vitiligo in a patient receiving infliximab for chronic plaque psoriasis. Dermatol. Ther. (2019) 32 e12917.
Ryu T.H., Lee D.W., Choi J.E., Ahn H.H., Kye Y.C., Seo S.H. A Type II segmental vitiligo developed under infliximab treatment for ulcerative colitis. Ann. Dermatol. (2017) 29 826.
Luber R.P., Chamberlain A.J., Sparrow M.P. New onset vitiligo following commencement of infliximab in Crohn disease. Intern. Med. J. (2017) 47 972-973.
Carvalho C.L.D.B., Ortigosa L.C.M. Segmental vitiligo after infliximab use for rheumatoid arthritis-a case report. An. Bras. Dermatol. (2014) 89 154-156.
Mattox A.R., Chappell J.A., Hurley M.Y. New-onset vitiligo during long-term, stable infliximab treatment of pityriasis rubra pilaris. J. Drugs Dermatol. (2013) 12 217-219.
Webb K.C., Tung R., Winterfield L.S. et al. Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo. Br. J. Dermatol. (2015) 173 641-650.
Bae J.M., Kim M., Lee H.H. et al. Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study. J. Invest. Dermatol. (2018) 138 768-774.
Moretti S., Spallanzani A., Amato L. et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res. (2002) 15 87-92.
Simsek H., Savas C., Akkiz H., Telatar H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatol. Basel Switz. (1996) 193 65-66.
Nouri K., Busso M., Machler B.C. Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C. Cutis (1997) 60 289-290.
Guney E., Akcali G., Akcay B.I. et al. Vitiligo in a patient treated with interferon alpha-2a for Behçet’s disease. Case Rep. Med. (2012) 2012 387140.
Oiso N., Sato M., Kawada A. Vitiligo after combination therapy of pegylated interferon-α-2a, ribavirin and vitamin D in a patient with chronic hepatitis C. J. Dermatol. (2013) 40 772-773.
Anbar T.S., Abdel-Rahman A.T., Ahmad H.M. Vitiligo occurring at site of interferon-alpha 2b injection in a patient with chronic viral hepatitis C: a case report. Clin. Exp. Dermatol. (2008) 33 503.
Méry-Bossard L., Bagny K., Chaby G. et al. New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases. J. Eur. Acad. Dermatol. Venereol. (2017) 31 181-186.
Ruck T., Pfeuffer S., Schulte-Mecklenbeck A. et al. Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells. Neurology (2018) 91 e2233-e2237.